



PRESS RELEASE

For immediate release

PERCEPTRONIX' SCIENTISTS PUBLISH PAPER IN JOURNAL OF THORACIC ONCOLOGY

Vancouver, BC November 8, 2007 – Perceptronix Medical Inc. (Perceptronix) is pleased to report positive study results from their LungSign™ test for early detection of Lung Cancer. The study, '*Detection of Lung Cancer by Automated Sputum Cytometry*' was published in the November 2007 issue of the prestigious Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

“The results represent a significant advance in the early detection of lung cancer, a disease that has had little progress in the last few decades,” commented Dr. Bojana Turic, President and CEO, Perceptronix. “This test will provide a much needed tool for improving current diagnostics for the earlier detection of lung cancer. We were pleased the study was accepted for publication in this international peer-reviewed journal. ”

“The need for new tools to aid in the diagnosis of lung cancer is great” added John Pysk, Director of Sales and Marketing at Perceptronix. “This safe, painless and convenient test may improve patient outcomes because of its ability to detect cancer even when it is presenting in its earliest stages. It is based on an innovative marker in sputum that is highly correlated with the presence of lung malignancy - even in early stage disease”.

LungSign is the first test to market that provides both an independent result to help with the early detection of lung cancer and a useful complement to current radiological detection methods.

The paper concludes that LungSign is a simple, non-invasive test that is sensitive to detecting early stage cancer. “While there are no current tests available that provide 100 percent diagnostic accuracy, the LungSign test may provide clinicians with additional information helping to detect lung cancer at an earlier and more treatable stage of the disease,” stated Dr. Roger Kemp, lead author of the paper and Director of Clinical Research at Perceptronix.

Lung cancer is the most common cause of cancer-related death in men and the second most common in women. Responsible for an estimated 1.3 million deaths worldwide annually, the most significant risk factor for developing lung cancer is long-term exposure to inhaled carcinogens, especially tobacco smoke. The two main types of lung cancer are small cell lung cancer and non-small cell lung cancer. Currently, the 5-year survival rates are poor, but earlier detection offers hope in improving such outcomes.



The paper appears in the Journal of Thoracic Oncology, Volume 2, Number 11, November 2007 issue.

About Perceptronix Medical Inc.

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

Perceptronix is focused on offering quantitative image cell analysis services for early cancer detection. Perceptronix' products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients' lives.

This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

- 30 -

Media Contact:

Amanda Smith, BSc
Smith Biotech
Phone: (778) 846-4116
amanda@smithbiotech.com